Humacyte, Inc. - Common Stock HUMA 深 滬
已收盤 12-19 16:00:00 美东时间
1.11
0.000
0.00%
華盛通- 最 高1.16
- 今 開1.128
- 成交量 727.50万股
- 最 低 1.10
- 昨 收 1.11
- 總市值 1.76亿
- 52周最高 5.48
- 市盈率 靜 --
- 換手率 4.58%
- 52周最低 1.0601
- 委 比 -65.31%
- 總股本 1.59亿
- 歷史最高 17.45
- 量 比 1.54
- 振 幅 5.41%
- 歷史最低 1.0601
- 每 手 1
- 風險率 1.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Humacyte Terminates Revenue Interest And Option Agreements Dated May 12, 2023; Co To Pay Pay $38M Cash And Issue 5,725,190 Shares In Registered Offering
On December 15, 2025, the Humacyte, Inc. (the "Company") and Humacyte Global, Inc. ("Global") agreed with TPC Investments III LP and TPC Investments Solutions LP (collectively, the "Purchasers"), and Hook SA LLC, as
12-15 22:18
Humacyte Terminates $80M Open Market Sale Agreement With Jefferies, Effective December 1; Company Is Not Subject To Any Termination Penalties Related To The Termination Of The Agreement
As previously disclosed, on September 1, 2022, Humacyte, Inc. (the "Company") entered into an Open Market Sale Agreement™ (the "Agreement") with Jefferies LLC ("Jefferies"), under which the Company may offer and
11-27 06:14
美股大行评级 | 最高130美元！11家大行集体上调沃尔玛目标价；戴康工业、Gap、罗斯百货等均或多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Fractyl Health"买入"评级，目标价从6美元升至8美元；HC Wainwright & Co.：维持MediWound"买入"评级，目标价从31美元升至36美元
11-24 11:23
BTIG Reiterates Buy on Humacyte, Maintains $6 Price Target
BTIG analyst Ryan Zimmerman reiterates Humacyte (NASDAQ:HUMA) with a Buy and maintains $6 price target.
11-21 19:13
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
11-12 19:11
Insights Ahead: Humacyte's Quarterly Earnings
Humacyte (NASDAQ:HUMA) is gearing up to announce its quarterly earnings on Wedn...
11-12 02:04
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target
D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.
11-11 02:14
Humacyte Presents 2-Yr Results From V007 Phase 3 Clinical Trial Of ATEV In AV Access For Hemodialysis Patients At ASN Kidney Week 2025
– The ATEV™ was observed to have superior duration of use over 24 months compared to autogenous fistula in high-need subgroups with historically poor outcomes with AV fistula procedures –– The significantly longer
11-10 21:10
